DECRYPTION – The first clinical trials have shown protection well below the levels required by the WHO. The blow is hard for French research.
The Institut Pasteur announces the abandonment of its work for its most advanced vaccine candidate against Covid-19. In question, an effectiveness which appears very insufficient, especially with regard to the results obtained by the vaccines already marketed. “It’s a very big disappointment, reacts Christophe d’Enfert, scientific director at the Institut Pasteur. The induced immune responses were found to be lower than those seen in people cured of a natural infection. We would undoubtedly have been well below the 50% efficiency required by the WHO. ”
From a health point of view, the consequences of this abandonment are all relative as the French project had fallen behind. No dose had therefore been pre-ordered by the European Union, and the most optimistic forecasts did not envisage marketing before the end of 2021. But the blow is hard for French research, especially since it arrives a few weeks after Sanofi warned of a significant delay
This article is for subscribers only. You have 77% left to discover.
Subscribe: 1 € the first month
Can be canceled at any time
Already subscribed? Log in